Literature DB >> 19832854

The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.

Athanasios D Anastasilakis1, Stergios A Polyzos, Avraam Avramidis, Konstantinos A Toulis, Athanasios Papatheodorou, Evangelos Terpos.   

Abstract

OBJECTIVE: Parathyroid hormone increases the differentiation of osteoblast precursors through canonical wingless (Wnt) signalling, resulting in an osteoanabolic effect. We aimed to evaluate serum levels of the Wnt-inhibitor Dickkopf-1 (Dkk-1) in postmenopausal women with established osteoporosis and their changes with teriparatide (TPTD - human recombinant PTH 1-34). DESIGN AND PATIENTS: A total of 31 postmenopausal Caucasian women with established osteoporosis (mean age 66.3 +/- 1.4 years) received daily injections of 20 microg TPTD for 18 months. Follow-up was continued for another 6 months after treatment discontinuation (total duration of treatment 24 months). MEASUREMENTS: Serum samples for total calcium (Ca), intact PTH (iPTH), bone-specific alkaline phosphatase, C-terminal cross-linking telopeptide of type 1 collagen (CTx) and Dkk-1 were obtained at baseline, and at 6, 18 and 24 months after TPTD initiation. Lumbar spine bone mineral density (BMD) was measured before and after 18 months of TPTD treatment. A total of 16 age- and gender-matched healthy controls were also analysed at baseline.
RESULTS: Serum Dkk-1 levels at baseline were significantly higher in osteoporotic women compared with that in controls (P < 0.002). Dkk-1 increased significantly during TPTD administration (P < 0.044) and decreased to baseline 6 months after TPTD discontinuation. Dkk-1 change was positively correlated to Ca (r = 0.530, P = 0.004) and negatively correlated to iPTH change (r = -0.398, P = 0.040). There was no correlation between Dkk-1 and BMD changes.
CONCLUSIONS: Our data suggest that Dkk-1 levels are increased in women with postmenopausal osteoporosis. TPTD therapy results in further increase of Dkk-1 that may be compensative to TPTD-induced enhanced Wnt signalling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19832854     DOI: 10.1111/j.1365-2265.2009.03728.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  19 in total

1.  Association of serum Dkk-1 levels with β-catenin in patients with postmenopausal osteoporosis.

Authors:  Jun Tian; Xiao-Juan Xu; Lin Shen; Yan-Ping Yang; Rui Zhu; Bo Shuai; Xi-Wen Zhu; Cheng-Gang Li; Chen Ma; Lin Lv
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-04-16

Review 2.  Parathyroid hormone analogues in the treatment of osteoporosis.

Authors:  Marius E Kraenzlin; Christian Meier
Journal:  Nat Rev Endocrinol       Date:  2011-07-12       Impact factor: 43.330

Review 3.  Role of fibroblast growth factor 2 and Wnt signaling in anabolic effects of parathyroid hormone on bone formation.

Authors:  Yurong Fei; Marja M Hurley
Journal:  J Cell Physiol       Date:  2012-11       Impact factor: 6.384

4.  Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.

Authors:  Fatma Gossiel; Jessica R Scott; Margaret A Paggiosi; Kim E Naylor; Eugene V McCloskey; Nicola F A Peel; Jennifer S Walsh; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2018-04-01       Impact factor: 5.958

Review 5.  The Utility of Biomarkers in Osteoporosis Management.

Authors:  Patrick Garnero
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

Review 6.  Parathyroid hormone: anabolic and catabolic actions on the skeleton.

Authors:  Barbara C Silva; John P Bilezikian
Journal:  Curr Opin Pharmacol       Date:  2015-04-05       Impact factor: 5.547

7.  Dickkopf 1 protein circulating levels as a possible biomarker of functional disability and chronic damage in patients with rheumatoid arthritis.

Authors:  Ana M Santos; Eugenia-Lucía Saldarriaga; Rodrigo Giraldo-Bustos; Jesus Giovanny Ballesteros-Muñoz; Juan C Rueda; Francy-Milena Cuervo; José-Ignacio Angarita; Andrés Y Vásquez; Sofía Arias-Correal; Camilo A González; Pedro Santos-Moreno; John Londono
Journal:  Clin Rheumatol       Date:  2017-12-27       Impact factor: 2.980

8.  Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.

Authors:  C Tsentidis; D Gourgiotis; L Kossiva; A Marmarinos; A Doulgeraki; K Karavanaki
Journal:  Osteoporos Int       Date:  2016-10-20       Impact factor: 4.507

Review 9.  Current and future treatment options in osteoporosis.

Authors:  Linda Brewer; David Williams; Alan Moore
Journal:  Eur J Clin Pharmacol       Date:  2011-02-16       Impact factor: 2.953

10.  Regulatory pathways associated with bone loss and bone marrow adiposity caused by aging, chemotherapy, glucocorticoid therapy and radiotherapy.

Authors:  Kristen R Georgiou; Susanta K Hui; Cory J Xian
Journal:  Am J Stem Cells       Date:  2012-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.